7 results
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
Vasculitis Management - ACR ... Guidelines for Treatment ... • Giant Cell Arteritis ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
Giant Cell Arteritis ... - ACR/VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... Constitutional symptoms, Arthritis ... NPSLE rare, Malar rash ... 40, F:M 9:1 • Clinical ... Manifestations: Malar rash
Takayasu's Arteritis (TAK) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active TAK not on
Takayasu's Arteritis ... - ACR/VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
) Suspect: Clinical ... erythematosus (ACLE ... Malignancy (e.g. hematologic ... lymphoproliferative syndrome Clinical ... vein thrombosis Hematologic
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
disease • Systemic lupus ... Fever is the main clinical ... Petechial or purpuric rash ... SJIA], systemic lupus ... Treatment: • Corticosteroids
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
to 1:1 F:M • Clinical ... Constitutional symptoms, Arthritis ... NPSLE rare, Malar rash ... #DIL #rheumatology ... #diagnosis #treatment